Skip to main content
Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial.
- Author(s): Schiffmann, Raphael;
- Bichet, Daniel G;
- Jovanovic, Ana;
- Hughes, Derralynn A;
- Giugliani, Roberto;
- Feldt-Rasmussen, Ulla;
- Shankar, Suma P;
- Barisoni, Laura;
- Colvin, Robert B;
- Jennette, J Charles;
- Holdbrook, Fred;
- Mulberg, Andrew;
- Castelli, Jeffrey P;
- Skuban, Nina;
- Barth, Jay A;
- Nicholls, Kathleen
- et al.
Published Web Locationhttps://doi.org/10.1186/s13023-018-0813-7
BackgroundFabry disease is frequently characterized by gastrointestinal symptoms, including diarrhea. Migalastat is an orally-administered small molecule approved to treat the symptoms of Fabry disease in patients with amenable mutations.
MethodsWe evaluated minimal clinically important differences (MCID) in diarrhea based on the corresponding domain of the patient-reported Gastrointestinal Symptom Rating Scale (GSRS) in patients with Fabry disease and amenable mutations (N = 50) treated with migalastat 150 mg every other day or placebo during the phase 3 FACETS trial (NCT00925301).
ResultsAfter 6 months, significantly more patients receiving migalastat versus placebo experienced improvement in diarrhea based on a MCID of 0.33 (43% vs 11%; p = .02), including the subset with baseline diarrhea (71% vs 20%; p = .02). A decline in kidney peritubular capillary globotriaosylceramide inclusions correlated with diarrhea improvement; patients with a reduction > 0.1 were 5.6 times more likely to have an improvement in diarrhea than those without (p = .031).
ConclusionsMigalastat was associated with a clinically meaningful improvement in diarrhea in patients with Fabry disease and amenable mutations. Reductions in kidney globotriaosylceramide may be a useful surrogate endpoint to predict clinical benefit with migalastat in patients with Fabry disease.
Trial registrationNCT00925301 ; June 19, 2009.
For improved accessibility of PDF content, download the file to your device.